SEC Form 4 · accession 0001415889-17-001447
ACADIA PHARMACEUTICALS INC · ACAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Glenn Baity
Officer — EVP AND GC
Period of report
Aug 30, 2017
Accepted (ET)
Sep 1, 2017 · 5:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070494
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 30, 2017 | M | 16,507 | $1.62 | A | 94,163 | D | |
| Common StockF2 | Aug 30, 2017 | S | 26,507 | $34.8706 | D | 67,656 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $1.62 | Aug 30, 2017 | M | 16,507 | D | — | Mar 24, 2021 | Common Stock | 16,507 | 14,000 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.87 to $34.88 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- F325% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.